Can creatine supplementation form carcinogenic heterocyclic amines in humans?

Imagem de Miniatura
Arquivos
art_PEREIRA_Can_creatine_supplementation_form_carcinogenic_heterocyclic_amines_in_2015.PDF (387.42 KB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
PEREIRA, Renato Tavares dos Santos
DOERR, Felipe Augusto
PINTO, Ernani
SOLIS, Marina Yazigi
ARTIOLI, Guilherme Giannini
FERNANDES, Alan Lins
MURAI, Igor Hisashi
DANTAS, Wagner Silva
Citação
JOURNAL OF PHYSIOLOGY-LONDON, v.593, n.17, p.3959-3971, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Creatine supplementation has been associated with increased cancer risk. In fact, there is evidence indicating that creatine and/or creatinine are important precursors of carcinogenic heterocyclic amines (HCAs). The present study aimed to investigate the acute and chronic effects of low- and high-dose creatine supplementation on the production of HCAs in healthy humans (i.e. 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (8-MeIQx), 2-amino-(1,6-dimethylfuro[3,2-e]imidazo[4,5-b])pyridine (IFP) and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (4,8-DiMeIQx)). This was a non-counterbalanced single-blind crossover study divided into two phases, in which low- and high-dose creatine protocols were tested. After acute (1 day) and chronic supplementation (30 days), the HCAs PhIP, 8-MeIQx, IFP and 4,8-DiMeIQx were assessed through a newly developed HPLC-MS/MS method. Dietary HCA intake and blood and urinary creatinine were also evaluated. Out of 576 assessments performed (from 149 urine samples), only nine (3 from creatine and 6 from placebo) showed quantifiable levels of HCAs (8-MeIQx: n=3; 4,8-DiMeIQx: n=2; PhIP: n=4). Individual analyses revealed that diet rather than creatine supplementation was the main responsible factor for HCA formation in these cases. This study provides compelling evidence that both low and high doses of creatine supplementation, given either acutely or chronically, did not cause increases in the carcinogenic HCAs PhIP, 8-MeIQx, IFP and 4,8-DiMeIQx in healthy subjects. These findings challenge the long-existing notion that creatine supplementation could potentially increase the risk of cancer by stimulating the formation of these mutagens.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/11974
Referências
  1. Agence Francaise de Securite Sanitaire et Alimentaire, 2001, OP FRENCH AG FOOD SA
  2. Almeida AM, 2002, J CHROMATOGR B, V774, P215, DOI 10.1016/S1570-0232(02)00244-1
  3. AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1
  4. Benzi G, 2000, PHARMACOL RES, V41, P255, DOI 10.1006/phrs.1999.0618
  5. Breslow RA, 2000, CANCER CAUSE CONTROL, V11, P419, DOI 10.1023/A:1008996208313
  6. Brudnak MA, 2004, TOXICOL LETT, V150, P123, DOI 10.1016/j.toxlet.2004.01.013
  7. Cooper KM, 2014, J CHROMATOGR A, V1358, P20, DOI 10.1016/j.chroma.2014.06.061
  8. Fu YF, 2014, J CHROMATOGR A, V1333, P45, DOI 10.1016/j.chroma.2014.01.057
  9. Gualano B., 2010, EUR J APPL PHYSL, V111, P749
  10. Gualano B, 2012, AMINO ACIDS, V43, P519, DOI 10.1007/s00726-011-1132-7
  11. Gualano B, 2014, EXP GERONTOL, V53, P7, DOI 10.1016/j.exger.2014.02.003
  12. Gualano B, 2008, EUR J APPL PHYSIOL, V103, P33, DOI 10.1007/s00421-007-0669-3
  13. Gualano B, 2009, AM J KIDNEY DIS, V55, pe7
  14. Harris RC, 1997, RES VET SCI, V62, P58, DOI 10.1016/S0034-5288(97)90181-8
  15. Hayashi AP, 2014, LUPUS, V23, P1500, DOI 10.1177/0961203314546017
  16. Holland RD, 2005, CHEM RES TOXICOL, V18, P579, DOI 10.1021/tx049675w
  17. Kreider RB, 1998, MED SCI SPORT EXER, V30, P73, DOI 10.1097/00005768-199801000-00011
  18. Kreider RB, 2003, MOL CELL BIOCHEM, V244, P95, DOI 10.1023/A:1022469320296
  19. Li N, 2015, BRIT J CANCER, V112, P1247, DOI 10.1038/bjc.2015.26
  20. Lugaresi R, 2013, J INT SOC SPORT NUTR, V10, DOI 10.1186/1550-2783-10-26
  21. MANABE S, 1992, CARCINOGENESIS, V13, P827, DOI 10.1093/carcin/13.5.827
  22. Murray S, 2001, CARCINOGENESIS, V22, P1413, DOI 10.1093/carcin/22.9.1413
  23. Neves M, 2011, APPL PHYSIOL NUTR ME, V36, P419, DOI [10.1139/h11-014, 10.1139/H11-014]
  24. OHGAKI H, 1991, MUTAT RES, V259, P399, DOI 10.1016/0165-1218(91)90130-E
  25. OVERVIK E, 1989, CARCINOGENESIS, V10, P2293, DOI 10.1093/carcin/10.12.2293
  26. Pfau W, 2006, FOOD CHEM TOXICOL, V44, P2086, DOI 10.1016/j.fct.2006.07.011
  27. Poortmans JR, 1997, EUR J APPL PHYSIOL O, V76, P566, DOI 10.1007/s004210050291
  28. Poortmans JR, 2005, MED SCI SPORT EXER, V37, P1717, DOI 10.1294/01.mss.0000176398.64189.e6
  29. Poortmans JR, 1999, MED SCI SPORT EXER, V31, P1108, DOI 10.1097/00005768-199908000-00005
  30. RobbanaBarnat S, 1996, ENVIRON HEALTH PERSP, V104, P280, DOI 10.2307/3432886
  31. SKOG K, 1993, FOOD CHEM TOXICOL, V31, P655, DOI 10.1016/0278-6915(93)90049-5
  32. Skog KI, 1998, FOOD CHEM TOXICOL, V36, P879, DOI 10.1016/S0278-6915(98)00061-1
  33. Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x
  34. Terjung RL, 2000, MED SCI SPORT EXER, V32, P706
  35. VIKSE R, 1993, ACTA VET SCAND, V34, P363
  36. Wyss M, 2000, PHYSIOL REV, V80, P1107
  37. YANAGISAWA H, 1986, BIOCHEM BIOPH RES CO, V138, P1084, DOI 10.1016/S0006-291X(86)80393-X
  38. Yoshizumi Wyndie M., 2004, Journal of Herbal Pharmacotherapy, V4, P1, DOI 10.1300/J157v04n01_01

Coleções
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/12
Artigos e Materiais de Revistas Científicas - ODS/03